New Tool Allows for an Alternate Method of Prostate Cancer Diagnosis
April 1, 2011
• Test conducted in the non-cancerous part of the prostate.
• May aid in localization of cancer lesion within the prostate gland.
PHILADELPHIA — Researchers have found that it may not be necessary to look for tumors directly in patients with prostate cancer — analyzing non-tumor tissue may be an effective option, according to study results published in Cancer Research, a journal of the American Association for Cancer Research.
“A biopsy needle does not need to hit a tumor to detect the presence of tumor,” said lead researcher Dan Mercola, M.D., Ph.D., professor of pathology and laboratory medicine at the University of California at Irvine. “It is reminiscent of the game Battleship; we can detect more cancer cases using 12 shots with a biopsy needle than would otherwise be the case because we have made the ships bigger.”
More than 1 million prostate biopsies are performed in the United States each year, and these diagnostic tests can miss up to 30 percent of clinically significant prostate cancers. As many as one third of patients receive repeat biopsies within a year due to equivocal first results, Mercola said. Based on these study results, physicians could possibly detect changes in non-tumor tissue that indicate a tumor may be present, which could allow patients to be given a follow-up biopsy sooner.
“Changes in the non-tumor tissue surrounding the tumor have long been considered to be important to tumor growth. Interfering with this process could have therapeutic value,” he said. “The information in non-tumor tissue indicating ‘presence of tumor’ or not indicates who needs urgent re-biopsy and allows patients to consider alternative therapies to surgery or radiation such as neoadjuvant therapy or prostate cancer prevention treatment.”
Mercola and colleagues obtained 364 samples from men of all races who had biopsies for possible prostate cancer, or had prostatectomies to remove cancer, as well as control prostates from donors that had died of causes other than prostate cancer.
They observed changes in the nearby non-tumor tissue and found that changes in gene expression in normal tissue could be detected up to a few millimeters from prostate cancer.
“It is known that at least some prostate cancers cause a reaction in nearby stroma,” Mercola said. “However, we were surprised that a reaction may occur for most tumors, and that this response in non-tumor tissue may extend for many millimeters from the tumor.”
Ruoxiang Wang, M.D., Ph.D., a research scientist and associate professor in the department of medicine at Cedars-Sinai Medical Center, Los Angeles, said this study represents “one of the few painstaking attempts to define the pathology of tumor-associated stroma in prostate cancer patients…this study is the first to use clinical specimens in such studies in large scale, while the findings are in such a high statistical significance.”
“It is hoped that the large sample size and the high statistical significance of this study may help to ensure a better follow-up, and some of the defined stromal markers will eventually be validated with clinical values,” he said.
Further studies will be required to confirm the findings, and before urologists will likely be able to use a diagnosis based on non-tumor tissue for recommending surgery or other radical treatment, according to the researchers. Wang added that these results, if confirmed, could provide guidance to the understanding of the tumor microenvironment, as cancer-stromal interaction plays a pivotal role in prostate cancer progression and bone metastasis.
# # #
Follow the AACR on Twitter: @aacr #aacr
Follow the AACR on Facebook: http://www.facebook.com/aacr.org
The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.